Effects of Icotinib on Advanced Non-Small Cell Lung Cancer with Different EGFR Phenotypes

EGFR-Targeted Therapy for Non-Small Cell Lung Cancer: Focus on EGFR Oncogenic Mutation

(2013) Alberto Antonicelli et al.   International Journal of Medical Sciences

Impact of EGFR Inhibitor in Non–Small Cell Lung Cancer on Progression-Free and Overall Survival: A Meta-Analysis

(2013) Chee Khoon Lee et al.   JNCI-Journal of the National Cancer Institute

Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial

(2013) Yuankai Shi et al.   LANCET ONCOLOGY

Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial

(2013) Marina Chiara Garassino et al.   LANCET ONCOLOGY

Role of Erlotinib in the Treatment of Non-Small Cell Lung Cancer

(2012) Bilal Piperdi et al.   DRUGS

Icotinib (BPI-2009H), a novel EGFR tyrosine kinase inhibitor, displays potent efficacy in preclinical studies

(2011) Fenlai Tan et al.   LUNG CANCER

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

(2010) Makoto Maemondo et al.   NEW ENGLAND JOURNAL OF MEDICINE

EGFR-TKI and lung adenocarcinoma with CNS relapse: interest of molecular follow-up

(2009) A-M. Ruppert et al.   EUROPEAN RESPIRATORY JOURNAL

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

(2009) Tetsuya Mitsudomi et al.   LANCET ONCOLOGY

The EGFR inhibitor gefitinib suppresses recruitment of pericytes and bone marrow-derived perivascular cells into tumor vessels

(2009) Erika Iivanainen et al.   MICROVASCULAR RESEARCH

Alterations in Genes of the EGFR Signaling Pathway and Their Relationship to EGFR Tyrosine Kinase Inhibitor Sensitivity in Lung Cancer Cell Lines

(2009) Jeet Gandhi et al.   PLoS One

First- or Second-line Therapy with Gefitinib Produces Equal Survival in Non–Small Cell Lung Cancer

(2008) Jenn-Yu Wu et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Lung Cancer Screening with CT

(2008) Denise R. Aberle et al.   CLINICS IN CHEST MEDICINE

Gefitinib (ZD1839): Therapy in selected patients with non-small cell lung cancer (NSCLC)?

(2008) Diego Dongiovanni et al.   LUNG CANCER

Selective COX-2 inhibitor celecoxib combined with EGFR-TKI ZD1839 on non-small cell lung cancer cell lines: in vitro toxicity and mechanism study

(2008) Likun Chen et al.   MEDICAL ONCOLOGY